Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial).

Exploratory subgroup analyses of treatment effect on PVR by PH-specific therapy, CTEPH population, sex, WHO FC, dose group and NT-proBNP did not identify any differences between selexipag and placebo, except for race and geographical location, both of which showed a trend towards favouring placebo over selexipag for patients who were Asian and those from Asia/Latin America ( supplementary figure S2 ).

also in 53,322 other papers